Eli Lilly shares signal further upside as technical targets extend to $1,655
Eli Lilly shares are extending a powerful rally after climbing more than 70% from their 2026 low to a record high reached on Thursday. Technical indicators point to the potential for another advance, while key support levels now shape the risk to the bullish outlook.
Highlights
- Eli Lilly shares show upside potential, with technical targets at $1,494, $1,532, $1,579, and a Fibonacci-based projection of $1,655, according to LSEG data.
- Bollinger Bands, Relative Strength Index, and Moving Average Convergence Divergence all currently signal the potential for continued share price gains.
- A decline below the $1,377–$1,383 support range raises concerns among analysts, while a break under $1,333.22 would likely invalidate the bullish trend.
Technical setup points to higher price targets
As reported by Reuters, chart-based analysis suggests Eli Lilly may be preparing for another upward move after a period of consolidation following its rally from early October to early November.Analysts tracking the stock's price action are focusing on resistance levels, including so-called psychological markers based on large round numbers, which often act as potential ceilings or interim targets when shares trade in record-high territory.
Fibonacci projections based on Eli Lilly's rise from its Oct. 8 low to its Nov. 5 high, followed by a retreat to the Nov. 6 low, indicate a potential target of $1,655, according to data supplied by LSEG. Interim upside levels include $1,494, $1,532 and $1,579.
Momentum indicators and downside thresholds
Technical analysts say rallies typically unfold in phases, and Eli Lilly's recent sideways movement fits a consolidation pattern in which investors absorb earlier gains before a possible next leg higher.Bollinger Bands, the Relative Strength Index and Moving Average Convergence Divergence all indicate the shares could continue rising, reinforcing the bullish reading from the chart pattern.
Still, the outlook carries two-way risk. If Eli Lilly falls below the $1,377 to $1,383 range, analysts may begin to doubt the case for further gains, while a drop below $1,333.22 would likely end the current rally narrative.
Previously, we highlighted Nasdaq 100 consolidation as traders watched key resistance near 29,965 for a potential breakout.
Latest Investing News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
